论文部分内容阅读
目的探究消旋卡多曲治疗小儿急性水样腹泻的临床疗效。方法选取我院2015年8月-2016年3月收治的急性水样腹泻小儿患者38例,随机分为观察组和对照组各19例,对照组给予患者蒙脱石散治疗,观察组给予患者消旋卡多曲治疗,对比两组患儿的临床疗效、症状消失时间及不良反应。结果观察组患儿显效12例,有效6例,无效1例,总有效率为94.7%;对照组患儿显效8例,有效7例,无效4例,总有效率为78.9%;两组患儿治疗总有效率对比差异具有统计学意义(P<0.05)。观察组患儿症状和体征消失平均时间为(2.8±0.4)d;对照组患儿症状消失平均时间为(4.1±0.6)d;观察组患儿症状消失时间明显短于对照组,差异具有统计学意义(P<0.05)。观察组患儿出现1例呕吐症状,对照组患儿出现1例皮疹,两组患儿不良反应较轻,停药后自行消失,不良反应对比差异不明显。结论消旋卡多曲治疗小儿急性水样腹泻疗效确切,有效改善患儿临床症状,不良反应少且轻,值得临床推广应用。
Objective To investigate the clinical efficacy of racecadotril in the treatment of acute watery diarrhea in children. Methods Thirty-eight children with acute watery diarrhea treated in our hospital from August 2015 to March 2016 were randomly divided into observation group (19 cases) and control group (19 cases). Patients in the control group were treated with montmorillonite powder. Patients in observation group Racecadotril treatment, compared the clinical efficacy of two groups of children, symptoms disappear time and adverse reactions. Results The observation group of children markedly effective in 12 cases, effective in 6 cases, 1 case of ineffective, the total effective rate was 94.7%; control group of children markedly effective in 8 cases, effective in 7 cases, ineffective in 4 cases, the total effective rate was 78.9% The total effective rate of children compared with the difference was statistically significant (P <0.05). The average time of disappearance of symptoms and signs in the observation group was (2.8 ± 0.4) d, and the mean disappearance of symptoms in the control group was (4.1 ± 0.6) days. The disappearance time of symptoms in the observation group was significantly shorter than that in the control group Significance (P <0.05). One case of vomiting was observed in the observation group and one case of rash occurred in the control group. The adverse reactions in both groups were mild and disappeared after stopping. The difference in adverse reactions was not obvious. Conclusion Racecadotril treatment of children with acute watery diarrhea exact effect, effectively improve the clinical symptoms of children with less adverse reactions and light, worthy of clinical application.